Aspire Biopharma Advances Sublingual Aspirin and Caffeine Launch

Company Overview

ASPIRE BIOPHARMA HOLDINGS INC (Nasdaq: ASBP) is an early-stage biopharmaceutical company focused on developing sublingual drug delivery mechanisms. Founded in September 2021, the company utilizes patented nano-technology formulations that bypass the gastrointestinal tract to enable rapid absorption of active pharmaceutical ingredients. Aspire’s platform can be applied to various existing drugs and supplements, including analgesics and treatments for conditions such as erectile dysfunction and traumatic brain injury, aiming to improve onset time and dosage management.

Corporate Structure

Aspire Biopharma is headquartered in Humacao, Puerto Rico, and transitioned to a Nasdaq-listed company following its business combination with PowerUp Acquisition Corp., which was completed on February 17, 2025. The merger valued Aspire at a pre-money equity of approximately $316 million, facilitating access to public capital markets under the ticker ASBP. According to LinkedIn, the company has a workforce of 51–200 employees, covering roles in research and development, manufacturing partnerships, finance, logistics, and hospital account management.

Recent Developments and News

• February 20, 2025: ASBP common stock and warrants commenced trading on the Nasdaq Global Market and Nasdaq Capital Market.
• March 20, 2025: Contract manufacturer Glatt Air Techniques completed the first Good Manufacturing Practice (GMP) clinical batch of Aspire’s oral mucosal fast-acting aspirin. A bioavailability study in healthy volunteers was scheduled for April 2025, with a formal meeting with the FDA planned for the second quarter of 2025. Clinical trials for both low-dose preventive and high-dose pain relief aspirin formulations are expected in Fall 2025, with a request for fast-track FDA approval to follow.
• May 28, 2025: Aspire announced BUZZ BOMB™—a 50 mg sublingual caffeine pre-workout supplement—targeted for launch in the third quarter of 2025. Initial production by Desert Stream has begun, with expanded consumer testing planned for Q2 2025. The product will be presented at FITCON Expo in Salt Lake City (August 1–2, 2025) and The Fit Expo in Anaheim (August 2–3, 2025).
• Patent Filings: Aspire filed U.S. patent application 63/456,290 in March 2023 for its soluble powder formulation process, and application 63/702,381 on October 2, 2024, covering a high-dose aspirin micelle-based delivery technique.

Financial and Strategic Analysis

As of June 26, 2025, ASBP closed at USD 0.3058 per share, reflecting a 27.63% increase on a trading volume of 18,612,184 shares. Key metrics sourced from Yahoo Finance include:

Metric	Value
Previous Close (USD)	0.2358
Day’s Range (USD)	0.3362–0.7300
52-Week Range (USD)	0.2150–15.8000
Market Capitalization (USD)	11.76 million
Enterprise Value (USD)	17.18 million
Beta (5Y Monthly)	0.91
EPS (TTM)	–0.5800
Net Income (TTM)	–17.02 million
Total Cash (mrq)	1.35 million

Aspire’s strategy focuses on leveraging sublingual absorption to speed up treatment initiation and reduce gastrointestinal metabolism. The upcoming BUZZ BOMB™ launch aims to generate immediate revenue, while the high-dose aspirin program moves forward through clinical and regulatory milestones. Collaboration with Glatt Air Techniques and Desert Stream are set to enhance GMP manufacturing capabilities.

Market Position and Industry Context

Aspire Biopharma operates within the drug delivery innovation and therapeutic markets, addressing challenges in emergency cardiology and pain management, along with the sports nutrition segment. The global pre-workout supplement market is projected to reach USD 27.97 billion by 2030, with a compound annual growth rate (CAGR) of 5.9% from 2025 to 2030. Aspire’s entry into this market with its instant-absorption product distinguishes it from traditional powder-and-water formulations that typically take 20–30 minutes for effect. In cardiovascular care, its high-dose aspirin candidate aims for expedited FDA review under fast-track provisions.

TL;DR

ASBP shares closed at USD 0.3058 on June 26, 2025, following a 27.63% gain, driven by two key developments: the completion of a GMP clinical batch for fast-acting sublingual aspirin (with bioavailability studies scheduled for April 2025 and engagement with the FDA planned for Q2 2025) and the anticipated Q3 2025 launch of BUZZ BOMB™, a 50 mg sublingual caffeine pre-workout supplement. The company has a market cap of USD 11.8 million and is advancing both emergency-care and sports-nutrition products through patent protection, manufacturing partnerships, and planned clinical trial initiations through late 2025.